Search
Merck's Clesrovimab, a Long-Acting RSV Monoclonal Antibody, Proposed for Priority Review in China
1 day ago /
Read about 0 minute
Author：小编
On June 9, 2025, Merck's Clesrovimab received marketing authorization from the U.S. Food and Drug Administration (FDA). This groundbreaking medication represents the first single-dose RSV monoclonal antibody specifically designed for infants, catering to babies of all weight categories. Clesrovimab employs passive immunization to prevent RSV infection, boasting a safety profile comparable to that of a placebo. The approval of this innovative drug is anchored on the robust results obtained from pivotal clinical trials.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
